Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $13.59, for a total value of $59,796.00. Following the completion of the transaction, the chief executive officer now directly owns 737,767 shares in the company, valued at $10,026,253.53. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Atara Biotherapeutics, Inc. (ATRA) traded up 4.04% on Monday, reaching $14.15. The company’s stock had a trading volume of 188,985 shares. Atara Biotherapeutics, Inc. has a 12 month low of $11.80 and a 12 month high of $23.00. The firm’s 50 day moving average is $15.39 and its 200-day moving average is $15.07. The firm’s market cap is $432.41 million.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, equities research analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.90) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/30/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-4400-shares.html.

A number of institutional investors have recently modified their holdings of ATRA. Wells Fargo & Company MN boosted its position in Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock valued at $1,197,000 after buying an additional 4,791 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Atara Biotherapeutics by 5.3% in the first quarter. Bank of New York Mellon Corp now owns 120,097 shares of the biotechnology company’s stock valued at $2,468,000 after buying an additional 6,069 shares in the last quarter. Swiss National Bank boosted its position in Atara Biotherapeutics by 9.6% in the first quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 2,500 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Atara Biotherapeutics by 62.6% in the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock valued at $522,000 after buying an additional 9,774 shares in the last quarter. Finally, American International Group Inc. boosted its position in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares in the last quarter. Hedge funds and other institutional investors own 82.74% of the company’s stock.

Several research analysts have recently commented on the company. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a report on Friday, October 6th. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Canaccord Genuity reissued a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a report on Monday, September 11th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $24.40.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.